GlobeNewswire Inc | Feb 17, 2021 04:30PM EST

February 17, 2021

BOSTON, Feb. 17, 2021 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage rare liver disease company developing novel bile acid modulators, today announced the grant of inducement stock options exercisable for an aggregate of 18,500 shares of Albireos common stock. The stock options are exercisable at a price of $38.39 per share, the closing price of Albireos common stock on February 16, 2021, the grant date, and were granted as inducements material to the employees acceptance of employment with Albireo in accordance with Nasdaq Listing Rule 5635(c)(4). Each stock option has a 10-year term and vests over a four-year period, subject to the employees continued service with Albireo through the applicable vesting dates. The vesting schedule for each stock option is 25 percent on the one-year anniversary of the employees start date with Albireo and 75 percent in 12 equal quarterly installments thereafter. The stock options are subject to the terms and conditions of Albireos 2020 Inducement Equity Incentive Plan.

About AlbireoAlbireo Pharma is a clinical-stage biopharmaceutical company focused on the development of novel bile acid modulators to treat rare pediatric and adult liver diseases. Albireos lead product candidate, odevixibat, is being developed to treat rare pediatric cholestatic liver diseases with Phase 3 pivotal trials in PFIC, Alagille syndrome and biliary atresia. The Company completed IND-enabling studies for new preclinical candidate A3907 and plans to advance development in adult liver disease. Albireo was spun out from AstraZenecain 2008 and is headquartered inBoston, Massachusetts, with its key operating subsidiary inGothenburg, Sweden. TheBoston Business Journalnamed Albireo one of the 2020 Best Places to Work inMassachusetts for the second consecutive year. For more information on Albireo, please visitwww.albireopharma.com.

Media & Investor contacts:Colleen Alabiso, 857-356-3905, colleen.alabiso@albireopharma.com

Hans Vitzthum,LifeSci Advisors, LLC., 617-430-7578